Compare UCL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCL | BLRX |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 12.6M |
| IPO Year | 2019 | 2010 |
| Metric | UCL | BLRX |
|---|---|---|
| Price | $1.01 | $3.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 9.4K | ★ 44.6K |
| Earning Date | 05-20-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $2.15 |
| 52 Week High | $4.19 | $6.59 |
| Indicator | UCL | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 67.08 |
| Support Level | N/A | $3.48 |
| Resistance Level | $1.19 | $3.93 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 33.33 | 75.18 |
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.